Aaron Raphael is co-Managing Partner of the firm and Chair of the firm’s Chemistry and Life Sciences Team.
Aaron has over 20 years of patent law experience, focusing his practice on counseling U.S. and foreign clients in patent procurement, due diligence investigations, and preparing patentability, validity, and infringement opinions. Aaron has particular experience with patent prosecution in the areas of chemical, pharmaceutical, and medical diagnostic technologies. Aaron’s broader patent law experience includes strategic patent portfolio development, securing patent rights through the appellate process, and patent litigation. Aaron served on litigation teams for numerous Hatch‑Waxman litigations involving Abbreviated New Drug Applications, including paroxetine HCl (Paxil®), gemcitabine HCl (Gemzar®), and carbidopa/levodopa/entacapone (Stalevo®), and litigations involving etanercept (Enbrel®), the TRUEtrack® blood glucose meter, and metathesis catalysts (Grubbs Second Generation Catalyst). He has extensive experience in all aspects of pre-trial, trial, and post-trial proceedings.
Education:
- Emory University School of Law, J.D. 1999
- University of Michigan, B.S. in Chemistry 1996
Bar Admissions:
- Georgia
- District of Columbia
- Registered to practice before the U.S. Patent and Trademark Office
Prior Experience
- Georgia
- District of Columbia
- Registered to practice before the U.S. Patent and Trademark Office
Prior Experience
Aaron has practiced with the firm since its inception in 2009. Prior to that, he practiced for 10 years with the law firm of Finnegan LLP in Washington, DC., where he focused a significant portion of his practice on patent preparation and prosecution, and opinion drafting, particularly in the chemical, pharmaceutical, and cosmetic fields. He also practiced with the law firm of O’Brien Jones PLLC, a patent law firm boutique located in McLean, VA.
Publications & Presentations
Aaron is a frequent speaker in the areas of patent law and pharmaceuticals, including presenting on topics such as Drug Development and Intellectual Property, Novelty and Inherent Anticipation as Criteria for the Patentability of Crystalline Forms, and issues related to the Hatch-Waxman Act.